The U.S. Food and Drug Administration (FDA) has announced a funding opportunity titled “Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01)”, aimed at enhancing the bioequivalence assessment of generic orally inhaled drug products (OIDPs). This grant seeks to integrate machine learning (ML) with computational fluid dynamics (CFD) to streamline data processing, improve simulation speeds, and develop multiscale models for better prediction of drug deposition, while explicitly stating that clinical trials are not permitted under this funding opportunity. The FDA emphasizes the importance of this initiative in advancing the approval processes for generic OIDPs through innovative technological integration. The funding amount is capped at $300,000 for a single award, with applications due by March 31, 2024, and the application window opening on January 15, 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information.